- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Alternative Capital and Credit Funds
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology and Emerging Companies
- Government Matters
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Insurance Coverage and Recovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries
- Careers
- News & Insights
- About
- Languages
< Back to Bio
Evan Diamond
Evan Diamond
Insight 5 results
Article · Source: Law360
August 20, 2019
Fed. Circ.'s Arduous Legal Landscape For Diagnostic Patents
Client Alert
August 13, 2019
Federal Circuit Continues Trend of Finding Diagnostic Inventions to Be Patent-Ineligible
Article · Source: Bloomberg Law
April 29, 2019
Big Pharma Should Watch SCOTUS After Circuit Court Finds New Drug Uses Patentable
Article · Source: Law360
January 17, 2019
Takeaways From Fed. Circ. Hatch-Waxman IPR Case